Back to Search
Start Over
Abacavir/Dolutegravir/Lamivudine (Triumeq)–Induced Liver Toxicity in a Human Immunodeficiency Virus–Infected Patient
- Source :
- Open Forum Infectious Diseases
- Publication Year :
- 2017
- Publisher :
- Oxford University Press (OUP), 2017.
-
Abstract
- Drug-induced liver injury related to Triumeq (abacavir/lamivudine/dolutegravir) has not been reported in clinical trials. We report a case of hepatotoxicity related to Triumeq exposure in a human immunodeficiency virus–infected patient. Clinicians should remain aware of the risk for acute and late-onset hepatitis with these agents. Close monitoring is recommended.
- Subjects :
- 0301 basic medicine
hepatotoxicity
030106 microbiology
Human immunodeficiency virus (HIV)
Abacavir/dolutegravir/lamivudine
medicine.disease_cause
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Abacavir
medicine
030212 general & internal medicine
Hepatitis
Liver injury
Triumeq
human immunodeficiency virus
business.industry
Brief Report
abacavir
Lamivudine
medicine.disease
Virology
dolutegravir
3. Good health
Clinical trial
Infectious Diseases
Oncology
chemistry
Dolutegravir
business
liver injury
medicine.drug
Subjects
Details
- ISSN :
- 23288957
- Volume :
- 4
- Database :
- OpenAIRE
- Journal :
- Open Forum Infectious Diseases
- Accession number :
- edsair.doi.dedup.....8f39cc1496ea4b0f0abd572f177758f4